IC
NKTR icon

Intersect Capital’s Nektar Therapeutics NKTR Stock Holding History

Intersect Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-53
Closed -$8K – 271
2015
Q1 		$8K Buy
+53
New +$10.9K 0.01% 347

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Intersect Capital's NKTR Position: Q2 2015 in Review

Intersect Capital sold out of Nektar Therapeutics (NKTR) in Q2 2015, closing a stake of 53 shares — an estimated $8K sold.

Intersect Capital first reported a position in NKTR in Q1 2015 and held it in 1 quarter. The position peaked at $8K in Q1 2015. 181 funds tracked by Wall St. Rank hold NKTR as of Q2 2015.

  • Intersect Capital reported no remaining Nektar Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Intersect Capital sold 53 Nektar Therapeutics shares in Q2 2015, an estimated $8K.
  • Intersect Capital first reported a position in Nektar Therapeutics in Q1 2015 and held it in 1 quarter.
  • Intersect Capital's Nektar Therapeutics position peaked at $8K in Q1 2015.
  • 181 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2015.

Based on Intersect Capital's 13F filing for Q2 2015, filed 3 Aug 2015.